Q1 2024 EPS Estimates for Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Raised by Zacks Research

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Investment analysts at Zacks Research upped their Q1 2024 earnings per share estimates for shares of Zimmer Biomet in a research report issued to clients and investors on Monday, April 22nd. Zacks Research analyst U. Biswas now forecasts that the medical equipment provider will post earnings of $1.88 per share for the quarter, up from their prior forecast of $1.86. The consensus estimate for Zimmer Biomet’s current full-year earnings is $8.07 per share. Zacks Research also issued estimates for Zimmer Biomet’s Q1 2026 earnings at $2.26 EPS.

ZBH has been the subject of a number of other reports. TheStreet upgraded shares of Zimmer Biomet from a “c” rating to a “b-” rating in a report on Thursday, February 8th. Canaccord Genuity Group reaffirmed a “hold” rating and issued a $130.00 target price on shares of Zimmer Biomet in a research report on Friday, February 23rd. JPMorgan Chase & Co. lifted their price target on shares of Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a research note on Friday, February 9th. Raymond James lifted their target price on shares of Zimmer Biomet from $133.00 to $137.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Finally, Barclays lifted their target price on shares of Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a research note on Monday, February 12th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $139.39.

Zimmer Biomet Stock Up 0.6 %

ZBH opened at $121.52 on Wednesday. The stock has a market cap of $24.97 billion, a PE ratio of 24.85, a P/E/G ratio of 2.22 and a beta of 1.01. The company has a quick ratio of 0.78, a current ratio of 1.61 and a debt-to-equity ratio of 0.39. Zimmer Biomet has a 52 week low of $102.00 and a 52 week high of $149.25. The business’s fifty day simple moving average is $126.19 and its 200 day simple moving average is $119.44.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.15 by $0.05. The firm had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The business’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.88 earnings per share.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio is currently 19.63%.

Insider Buying and Selling

In related news, VP Chad F. Phipps sold 26,156 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the transaction, the vice president now owns 44,145 shares of the company’s stock, valued at $5,677,929.90. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.70% of the company’s stock.

Institutional Investors Weigh In On Zimmer Biomet

A number of hedge funds have recently added to or reduced their stakes in ZBH. Norges Bank purchased a new stake in Zimmer Biomet in the 4th quarter worth approximately $266,896,000. American Century Companies Inc. grew its stake in shares of Zimmer Biomet by 21.2% during the 3rd quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider’s stock valued at $545,809,000 after buying an additional 852,186 shares during the period. Boston Partners boosted its position in Zimmer Biomet by 29.2% during the 3rd quarter. Boston Partners now owns 2,694,832 shares of the medical equipment provider’s stock worth $302,366,000 after purchasing an additional 608,959 shares during the period. Barclays PLC lifted its holdings in Zimmer Biomet by 129.2% in the 3rd quarter. Barclays PLC now owns 1,072,494 shares of the medical equipment provider’s stock worth $120,356,000 after buying an additional 604,652 shares in the last quarter. Finally, Van ECK Associates Corp lifted its holdings in Zimmer Biomet by 23.7% in the 4th quarter. Van ECK Associates Corp now owns 2,838,558 shares of the medical equipment provider’s stock worth $345,452,000 after buying an additional 543,344 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.